Return to search

Escape Bio nabs $73m

Escape Bio, a developer of treatments for genetic neurodegenerative diseases, has raised $73 million in financing.

Escape Bio, a developer of treatments for genetic neurodegenerative diseases, has raised $73 million in financing. Wellington Management Company LLP led the round with participation from other backers that included Avidity Partners, CAM Capital, New Leaf Ventures, Rock Springs Capital, Surveyor Capital, Sphera Funds Management, OrbiMed, Novo Holdings, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners and Sutter Hill Ventures.

Source: Press Release